Oncolytics Biotech (Oncolytics Biotech) Retained Earnings : $-332.44 Mil (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Oncolytics Biotech's retained earnings for the quarter that ended in Dec. 2023 was $-332.44 Mil.

Oncolytics Biotech's quarterly retained earnings declined from Jun. 2023 ($-325.25 Mil) to Sep. 2023 ($-326.70 Mil) and declined from Sep. 2023 ($-326.70 Mil) to Dec. 2023 ($-332.44 Mil).

Oncolytics Biotech's annual retained earnings declined from Dec. 2021 ($-307.36 Mil) to Dec. 2022 ($-307.88 Mil) and declined from Dec. 2022 ($-307.88 Mil) to Dec. 2023 ($-332.44 Mil).

Oncolytics Biotech Retained Earnings Historical Data

The historical data trend for Oncolytics Biotech's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncolytics Biotech Retained Earnings Chart

Oncolytics Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-261.68

-286.60

-307.36

-307.88

-332.44

Oncolytics Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-307.88	-310.38	-325.25	-326.70	-332.44

Oncolytics Biotech Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Oncolytics Biotech (NAS:ONCY) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Oncolytics Biotech (Oncolytics Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

ONC:Canada

Address

322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5

Website

https://www.oncolyticsbiotech.com

Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.